OncoGxSelect-3 OncoGxOne™

OncoGxOne™ is a comprehensive Next Generation Sequencing (NGS) based test that profiles tumors for targeted therapy selection and chemotherapeutic tolerance.

  • 64 gene panel: 56 cancer related genes and 8 genes related to pharmacogenomics.
  • Comprehensive coverage of clinically actionable alterations found in multiple cancer types, covering all exons, 5’ and 3’ UTRs, and select introns known to harbor breakpoints.
  • Detects SNV, indel, CNV and gene fusion

View OncoGxSelect™ 12 gene panels

Types of Alterations Detected

SNVs1 OncoGxOne™

SNV

Fusions OncoGxOne™

Fusion

CNVS2 OncoGxOne™

CNV

Indels OncoGxOne™

Indel

Gene Therapeutic Area
ABL1 Chronic Myeloid Leukemia
AKT1 Breast Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer
ALK Anaplastic Large Cell Lymphoma
Inflammatory Myofibroblastic Tumor
Neuroblastoma
Non-Small Cell Lung Cancer
Rhabdomyosarcoma
ATM Diffuse Large B-Cell Lymphoma
Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia
AURKA Colorectal Cancer
BCL2 Lymphoma
BCL6 Lymphoma
BCR Chronic Myeloid Leukemia
BRAF Colorectal Cancer
Gastrointestinal Stromal Tumor
Glioma
Melanoma
Non-Small Cell Lung Cancer
Ovarian Cancer
Thyroid Cancer
BRCA1 Breast Cancer
Ovarian Cancer
BRCA2 Breast Cancer
 Ovarian Cancer
CCND1 Breast Cancer
Gene Therapeutic Area
CCNE1 Ovarian Cancer
CDK4 Breast Cancer
Liposarcoma
CEBPA Acute Myeloid Leukemia
CRLF2 Acute Lymphoblastic Leukemia
CTNNB1 Melanoma
DDR2 Non-Small Cell Lung Cancer
DNMT3A Acute Myeloid Leukemia
Myelodysplastic Syndromes
EGFR Colorectal Cancer
Glioblastoma
Head and Neck Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
ERBB2 Breast Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
ESR1 Breast Cancer
ETV6 Myelodysplastic Syndromes
Prostate Cancer
FGFR1 Breast Cancer
Non-Small Cell Lung Cancer
FGFR2 Breast Cancer
FGFR3 Bladder Cancer
Glioblastoma
FLT3 Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
GNA11 Melanoma
GNAQ Melanoma
Gene Therapeutic Area
HRAS Thyroid Cancer
IDH1 Acute Myeloid Leukemia
Glioma
IDH2 Acute Myeloid Leukemia
Glioma
JAK1 Acute Lymphoblastic Leukemia
Myeloproliferative Neoplasms
JAK2 Acute Lymphoblastic Leukemia
Myeloproliferative Neoplasms
KIT Acute Myeloid Leukemia
Gastrointestinal Stromal Tumor
Melanoma
Non-Small Cell Lung Cancer
Thymic Carcinoma
KMT2A Acute Myeloid Leukemia
KRAS Colorectal Cancer
Non-Small Cell Lung Cancer
Ovarian Cancer
Thyroid Cancer
MAP2K1 Melanoma
Non-Small Cell Lung Cancer
MET Non-Small Cell Lung Cancer
MPL Haematopoietic Neoplasms
MYC Small Cell Lung Cancer
NF1 Melanoma
Myelodysplastic Syndromes
NPM1 Anaplastic Large Cell Lymphoma
Acute Myeloid Leukemia
Gene Therapeutic Area
NRAS Colorectal Cancer
Melanoma
Non-Small Cell Lung Cancer
Thyroid Cancer
PDGFRA Gastrointestinal Stromal Tumor
PDGFRB Myeloid Neoplasms
PIK3CA Breast Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer
Ovarian Cancer
Squamous Cell Cervical Cancer
PTCH1 Gastric Cancer
Medulloblastoma
PTEN Breast Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer
Ovarian Cancer
RARA Acute Myeloid Leukemia
RET Non-Small Cell Lung Cancer
Thyroid Cancer
ROS1 Non-Small Cell Lung Cancer
RUNX1 Acute Myeloid Leukemia
Myelodysplastic Syndromes
SMO Basal Cell Carcinoma
Medulloblastoma
TP53 Cancer
Myelodysplastic Syndromes
TSC1 Bladder Cancer


Pharmacogenomics Related Genes

CYP2C8 CYP2D6 DPDYD MTHFR TPMT TYMS UGT1A1 XRCC1
Ado-trastuzumab emtansine (Kadcyla) Goserelin (Zoladex) Regorafenib (Stivarga)
Afatinib (Gilotrif) Imatinib (Gleevec) Ruxolitinib (Jakafi)
Alectinib (Alecensa) Ipilimumab (Yervoy) Sirolimus (Rapamune)
Anastrozole (Arimidex) Lapatinib (Tykerb) Sorafenib (Nexavar)
Bosutinib (Bosulif) Lenvatinib (Lenvima) Sunitinib (Sutent)
Cabozantinib (Cometriq) Letrozole (Femara) Tamoxifen (Soltamox; Nolvadex)
Ceritinib (Zykadia) Leuprolide (Lupron; Eligard) Temsirolimus (Torisel)
Cetuximab (Erbitux) Nilotinib (Tasigna) Tofacitinib (Xeljanz)
Cobimetinib (Cotellic) Nintedanib (OFEV) Toremifene (Fareston)
Crizotinib (Xalkori) Nivolumab (Opdivo) Trametinib (Mekinist)
Dabrafenib (Tafinlar) Olaparib (Lynparza) Trastuzumab (Herceptin)
Dasatinib (Sprycel) Osimertinib (Tagrisso) Tretinoin; ATRA (Vesanoid)
Erlotinib (Tarceva) Palbociclib (Ibrance) Vandetanib (Caprelsa)
Everolimus (Zortress; Affinitor) Panitumumab (Vectibix) Vemurafenib (Zelboraf)
Exemestane (Aromasin) Pazopanib (Votrient) Vismodegib (Erivedge)
Fulvestrant (Faslodex) Pertuzumab (Perjeta)
Gefitinib (Iressa) Ponatinib (Iclusig)
Arsenic trioxide (Trisenox) Docetaxel (Taxotere) Paclitaxel (Onxol; Abraxane)
Capecitabine (Xeloda) Fluorouracil (5-FU) Mercaptopurine (Purinethol)
Carboplatin (Paraplatin) Irinotecan (Camptosar) Thioguanine (Tabloid)
Cisplatin (Platinol) Leucovorin (Wellcovorin)
Cyclophosphamide (Endoxan) Oxaliplatin (Eloxatin)
Crenolanib (CP-868-596) Ganetespib (STA-9090) Retaspimycin (IPI-504)
Dacomitinib (PF-00299804) Neratinib (HKI-272) Rociletinib (CO-1686)
Dinaciclib (SCH-727965) Quizartinib (AC220) Selumetinib (AZD6244)
Dovitinib (TKI258) Refametinib (BAY86-9766) Tanespimycin (17-AAG)

OncoGxOne™ Report 

PGxOne_Plus_Sample_report_thumb-1 OncoGxOne™

OncoGxOne™ Informational Sheet